menu
    • menu

    Company profile for Melt Pharmaceuticals

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Smithfield BioScience transforms bioproducts into trusted, life-saving therapies through safe, reliable U.S.-based manufacturing.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    SWATI - Transforming science into solutions with 60+ years of expertise, global accreditations, and pioneering biotech innovation.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Headquartered just outside of Boston, Massachusetts, Melt Pharmaceuticals, Inc. is committed to the development and commercialization of a patented sublingual, needle and opioid-free procedural sedation and analgesic medication for preoperative use in human medical procedures. Melt Pharmaceuticals was spun out of Harrow Health in January 2019, after successfully completing our Series A financing. ImprimisRx (a subsidiary of...
    Headquartered just outside of Boston, Massachusetts, Melt Pharmaceuticals, Inc. is committed to the development and commercialization of a patented sublingual, needle and opioid-free procedural sedation and analgesic medication for preoperative use in human medical procedures. Melt Pharmaceuticals was spun out of Harrow Health in January 2019, after successfully completing our Series A financing. ImprimisRx (a subsidiary of Harrow Health) and several leading ophthalmologists developed a cGMP compounded version similar to our lead candidate (Melt-100) that has been dispensed more than 100,000 times by over 400 ophthalmologists.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Melt PharmaceuticalsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    200 Reservoir Street Suite 303 Needham, MA
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.meltpharma.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/melt-pharmaceuticals/about/?msgConversationId=6646191963097841664&msgOverlay=true
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DDL Conference

    Not Confirmed

    envelop Contact Supplier

    DDL Conference

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Harrow Announces Closing Of Acquisition Of Melt Pharmaceuticals
    Harrow Announces Closing Of Acquisition Of Melt Pharmaceuticals

    18 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/18/3189844/0/en/Harrow-Announces-Closing-of-Acquisition-of-Melt-Pharmaceuticals.html

    GLOBENEWSWIRE
    18 Nov 2025
    Share Share
    Harrow To Acquire Melt Pharmaceuticals
    Harrow To Acquire Melt Pharmaceuticals

    26 Sep 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/09/26/3156941/0/en/Harrow-to-Acquire-Melt-Pharmaceuticals.html

    GLOBENEWSWIRE
    26 Sep 2025
    Share Share
    Melt Pharmaceuticals Reports Positive Phase 3 Results for MELT-300
    Melt Pharmaceuticals Reports Positive Phase 3 Results for MELT-300

    20 Nov 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241120082898/en

    BUSINESSWIRE
    20 Nov 2024
    Share Share
    Melt Completes Dosing In MELT-300 Phase 3 For Cataract Surgery
    Melt Completes Dosing In MELT-300 Phase 3 For Cataract Surgery

    10 Oct 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241010858192/en

    BUSINESSWIRE
    10 Oct 2024
    Share Share
    Melt Pharmaceuticals Announces First Patient Dosed In Pivotal Phase 3 Program
    Melt Pharmaceuticals Announces First Patient Dosed In Pivotal Phase 3 Program

    06 Jun 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240606803052/en

    BUSINESSWIRE
    06 Jun 2024
    Share Share
    Melt Pharmaceuticals Closes $24 Million Series B Preferred Stock Financing
    Melt Pharmaceuticals Closes $24 Million Series B Preferred Stock Financing

    02 Apr 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240402844928/en

    BUSINESSWIRE
    02 Apr 2024
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search